Hatchtech finances Phase III DeOvo trials

The Australian speciality pharma company Hatchtech Pty Ltd has recently announced a new round of funding to support ongoing DeOvo trials, as well as a new CEO.

The company announced on 1 May 2012 that a total of AUD 7.8M has been raised to support Phase III trials of their DeOvo pedulicide and ovicide product, following strong Phase IIb trials.

The new Chief Executive Officer is Dr Ross Macdonald, who has previous experience of management in various speciality pharmaceutical companies, including the development of head lice products.